Latest News
From the Journals
Alcohol consumption may not influence breast cancer prognosis, study
The findings could help in developing specific guidelines related to the prevention of breast cancer recurrence and death in survivors.
News from the FDA/CDC
FDA approves elranatamab for multiple myeloma
Elranatamab previously received Breakthrough Therapy Designation for relapsed or refractory multiple myeloma.
News
FDA OKs talquetamab, a first-in-class myeloma tx
Accelerated approval has been granted by the FDA to talquetamab-tgvs, a bispecific antibody, for patients with myeloma who have undergone at least...
Latest News
Don’t skip contraception talk for women with complex health conditions
Primary care providers should discuss contraindications and contraception preferences for patients of child-bearing ability.
From the Journals
Sugary drinks may up risk for liver cancer, liver disease death
“Regardless of whether this is a surrogate marker for liver disease risk (such as fatty liver disease) or a consequence of the drink itself, it is...
From the Journals
Isometric exercise found optimal for lowering blood pressure?
The findings support the development of new exercise guidelines for blood pressure control, the authors said.
Conference Coverage
Genetic profiles affect smokers’ lung cancer risk
“This is the first study to validate genetic factors associated with people who appear to be resistant to developing tobacco-related lung cancer...
From the Journals
Female CRC survivors may experience long-term GI symptoms
“Our findings shed light on the importance of psychosocial support as well as lifestyle interventions (specifically nutritional management) in...
From the Journals
Older women risk overdiagnosis with mammograms: Study
Overdiagnosis carries the risks of complications from overtreatment, plus financial and emotional hardships.
From the Journals
Scalp cooling for chemo hair loss strikes out with patients
“The efficacy and tolerability of [scalp cooling] applied in a clinical routine setting ... appeared to be limited.”
From the Journals
For CLL, BTKi combo bests chemoimmunotherapy
Phase 3 FLAIR trial yields more evidence that younger patients fared better with two-drug combo than with FCR, the once-standard therapy.